TruSight Tumor 26
TruSight Tumor 170
TruSight Tumor 170, a next-generation sequencing assay designed to cover 170 genes associated with common solid tumors, is an enrichment-based targeted panel that simultaneously analyzes DNA and RNA, covering a wide range of genes and variant types. The comprehensive nature provides laboratories with a deep view into the genetics of cancer.
- Catalog ID(s)
- OP-101-1003: TruSight Tumor 170 – Library Prep for 24 Samples and Sequencing Consumables for 3 NextSeq runs
- OP-101-1004 (24 samples): TruSight Tumor 170 – Library Prep only for 24 Samples
Please rotate your device for details
| Species compatibility | Human | ||||||
|---|---|---|---|---|---|---|---|
| Recommended Illumina instrument | NextSeq 500/550 | HiSeq 2500 | NovaSeq 6000 (Dual Flow Cell)† | ||||
| Recommended samples per run and chemistry version (eg, 24 on v3) | 16 (8 DNA + 8 RNA) 10 if DNA only 16 is RNA only |
12 (6 DNA + 6 RNA) 6 if DNA only 12 if RNA only |
96 | 96 | 192 | ||
| Run mode | High Output | Rapid run mode | S1‡ | S2 | S4 | ||
| Max recommended read length | 2×101 bp | 2×101 | 2×100 bp | ||||
| Recommended secondary analysis (eg, MiSeq Reporter, Basespace) | TruSight Tumor 170 App | ||||||
| Recommended down stream analysis (eg, VariantStudio) | There are a number of third party solutions for analysis of variant calls produced by TruSight Tumor 170. Illumina is agnostic to which solution a customer would choose. Consult your Illumina sales representative for more information. | ||||||
* Library prep is compatible with all Illumina instruments. Recommended instruments chosen based on typical output and analysis need for selected application.
† Limited by index combinations (HT).
‡ NovaSeq S1 Reagent Kits are not currently available.